Investing.com - Charles River Laboratories (NYSE: CRL) reported third quarter EPS of $2.59, $0.17 better than the analyst estimate of $2.42. Revenue for the quarter came in at $1.01B versus the consensus estimate of $976M.
Guidance
Charles River Laboratories sees FY 2024 EPS of $10.10-$10.30 versus the analyst consensus of $10.00.
Charles River Laboratories's stock price closed at $188.68. It is down -6.12% in the last 3 months and up 3.21% in the last 12 months.
Charles River Laboratories saw 0 positive EPS revisions and 15 negative EPS revisions in the last 90 days. See Charles River Laboratories's stock price’s past reactions to earnings here.
According to InvestingPro, Charles River Laboratories's Financial Health score is "good performance".
Check out Charles River Laboratories's recent earnings performance, and Charles River Laboratories's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar